Rasch Analysis of the Motor Function Measure in Patients with Congenital Muscle Dystrophy and Congenital Myopathy
Vuillerot C, Rippert P, Kinet V, Renders A, Jain M, Waite M, Glanzman AM, Girardot F, Hamroun D, Iwaz J, Ecochard R, Quijano-Roy S, Bérard C, Poirot I, Bönnemann CG; CDM MFM study group.
Arch Phys Med Rehabil. 2014. 57(9-10):587-99.
The main goal of the study is to provide a valid outcome measure in order to monitor treatment effects in patients with congenital disorders of muscle.
289 patients, aged 5 to 77 years old, were enrolled and the three domains of the MFM were examined using a Rasch analysis.
The original 32-item MFM did not fit the Rasch model expectations enough in neither of its domains. Switching from a four- (0,1,2,3) to a three-category response scale (0,1,2) restored response order in 16 items. Various additional checks suggested the removal of seven items. The resulting 25-item MFM demonstrated a good fit to the Rasch model. Domain 1 was well targeted to the whole severity spectrum whereas Domains 2 and 3 were better targeted to severe cases. The reliability coefficients of the Rasch MFM-25 suggested sufficient ability for each summed score to distinguish between patient groups.
Keywords: Rasch analysis, congenital muscular dystrophy, congenital myopathy, motor function assessment, outcome measure
Articles dans les revues scientifiques
Measurements of Motor Function and Other Clinical Outcome Parameters in Ambulant Children with Duchenne Muscular Dystrophy
Nagy S, Schmidt S, Hafner P, Klein A, Rubino-Nacht D, Gocheva V, Bieri O, Vuillerot C, Bonati U, Fischer D. J Vis Exp. 2019. (143), e58784. Discussion in a video format on outcome measures, including MFM, used in the trial "Treatment with L-citrulline and metformin in...
Analysis of motor and respiratory function in Duchenne muscular dystrophy patients
Luiz LC, Lima Marson FA, Almeida CCB, Contrera Toro AAD, Nucci A, Ribeiro JD. Respir Physiol Neurobiol. 2019. 262:1-11. Assessment of motor and respiratory impairment of 19 Duchenne muscular dystrophy (DMD) patients. Non-ambulatory condition was associated with worse...
Assessment of disease progression in dysferlinopathy: A 1-year cohort study
Moore U, Jacobs M, James MK, Mayhew AG, Fernandez-Torron R, Feng J, Cnaan A, Eagle M, Bettinson K, Rufibach LE, Lofra RM, Blamire AM, Carlier PG, Mittal P, Lowes LP, Alfano L, Rose K, Duong T, Berry KM, Montiel-Morillo E, Pedrosa-Hernández I, Holsten S, Sanjak M,...
Disease duration and disability in dysfelinopathy can be described by muscle imaging using heatmaps and random forests.
Gómez-Andrés D, Díaz J, Munell F, Sánchez-Montáñez Á, Pulido-Valdeolivas I, Suazo L, Garrido C, Quijano-Roy S, Bevilacqua JA. Muscle Nerve. 2019. 59(4), 436-444. The manner in which imaging patterns change over the disease course and with increasing disability in...
Two-minute versus 6-minute walk distances during 6-minute walk test in neuromuscular disease: Is the 2-minute walk test an effective alternative to a 6-minute walk test?
Witherspoon JW, Vasavada R, Logaraj RH, Waite M, Collins J, Shieh C, Meilleur K, Bönnemann C, Jain M. Eur J Paediatr Neurol. 2019. 23 (1), 165-170. The primary objective of this study is to establish the utility of the 2-min walk test (2MWT) in patients with...
Correlation of phenotype with genotype and protein structure in RYR1-related disorders
Todd JJ, Sagar V, Lawal TA, Allen C, Razaqyar MS, Shelton MS, Chrismer IC, Zhang X, Cosgrove MM, Kuo A, Vasavada R, Jain MS, Waite M, Rajapakse D, Witherspoon JW, Wistow G, Meilleur KG. J Neurol. 2018. 265(11), 2506-2524. Variants in the skeletal muscle ryanodine...